EXEL Stock Price Forecast. Should You Buy EXEL?
Stock Details
EXEL 36
Exelixis (EXEL) PT Raised to $36 at BMO Capital
Etzer Darout·Wed Oct 30 2024
BMO Capital
EXEL 38
Exelixis price target raised to $38 from $33 at Truist
Asthika Goonewardene·Wed Oct 30 2024
Truist Financial
EXEL 36
Exelixis price target raised to $36 from $33 at Piper Sandler
Joseph Catanzaro·Wed Oct 30 2024
Piper Sandler
EXEL 38
Exelixis (EXEL) PT Raised to $38 at Citi
David Lebowitz·Wed Oct 30 2024
Citigroup
EXEL 28.5
Leerink Partners Reiterates Market Perform Rating on Exelixis (EXEL)
Christopher Liu·Wed Oct 16 2024
Leerink Partners
EXEL 34
Exelixis (EXEL) PT Raised to $34 at RBC Capital
Kennen MacKay·Wed Oct 16 2024
RBC Capital
EXEL 18
Goldman Sachs Reiterates Sell Rating on Exelixis (EXEL)
Chris Shibutani·Wed Oct 16 2024
Goldman Sachs
EXEL 33
Exelixis price target raised to $33 from $30 at Jefferies
Akash Tewari·Tue Oct 15 2024
Jefferies
EXEL 30
Morgan Stanley Out Mixed on Exelixis (EXEL), PT Raised to $30, 'ruling is short of a home run scenario'
Jeffrey Hung·Tue Oct 15 2024
Morgan Stanley
EXEL 33
Truist Securities Reiterates Buy Rating on Exelixis (EXEL)
Asthika Goonewardene·Mon Oct 14 2024
Truist Financial
EXEL 23
Stephens Reiterates Equal Weight Rating on Exelixis (EXEL)
Sudan Loganathan·Mon Oct 14 2024
Stephens
EXEL 28
Exelixis price target raised to $28 from $26 at Morgan Stanley
Jeffrey Hung·Fri Oct 11 2024
Morgan Stanley
EXEL 30
Exelixis initiated with a Neutral at UBS
Ashwani Verma·Thu Sep 19 2024
UBS
EXEL 31
Citi Reiterates Buy Rating on Exelixis (EXEL)
David Lebowitz·Mon Sep 16 2024
Citigroup
EXEL 30
Exelixis (EXEL) PT Raised to $30 at BofA Securities
Jason Gerberry·Wed Sep 04 2024
Bank of America Securities
EXEL 29
Exelixis (EXEL) PT Raised to $29 at H.C. Wainwright
Robert Burns·Thu Aug 08 2024
H.C. Wainwright
EXEL 29
Exelixis price target raised to $29 from $27 at JMP Securities
Silvan Tuerkcan·Wed Aug 07 2024
JMP Securities
EXEL 31
Citi Reiterates Buy Rating on Exelixis (EXEL)
David Lebowitz·Mon May 20 2024
New Street
EXEL 29
BMO Capital Reiterates Outperform Rating on Exelixis (EXEL)
George Farmertzer Darout·Mon May 20 2024
BMO Capital
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow